Not Yet RecruitingNot Applicable

Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment

84 participantsStarted 2026-06-08

Plain-language summary

This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment (MCI).

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Potential participant must be 65 years or older at the time of study screening.
✓. Potential participant must have MCI as defined by:
✓. Potential participant must have a study partner/informant defined as any acquaintance (e.g., family member, friend, neighbor, clinician) who has regular (at least monthly) interactions (in person or remote) with the participant.
✓. If potential participant reports use of medications typically prescribed for dementia such as, but not limited to, Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, Aducanumab, Leqembi or Lecanemab, Donanemab, the dose must be stable for at least 12 weeks prior to study enrollment.
✓. Potential participant must demonstrate adequate decisional capacity, in the judgment of the investigator, and capable of to making an informed decision regarding their participation in this research study.
✓. Potential participant must be likely able to complete all study activities and outcome measures in the judgment of the investigator.
✓. Potential participant must have the visual, auditory, and motors capacity to use the computerized intervention in the judgment of the investigator.
✓. Potential participant must be able to communicate in either English or French.

Exclusion criteria

✕. Potential participant has an existing diagnosis of major neurocognitive disorder at screening (DSM-IV).
✕. Potential participant who answered 'yes' to question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS or 'yes' to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the C-SSRS "Suicidal Behavior" if the ideation or behavior occurred within 2 months from Participant's date of consent (as recommended by the FDA for treatment trials.)
✕. Potential participant scores \>10 on the Geriatric Depression Scale - Short Form (GDS-SF).
✕. Potential participant has previously completed 10 or more hours of the computerized cognitive intervention program manufactured by Posit Science.
✕. Potential participant is participating in a concurrent clinical trial (involving an investigational pharmaceutical, behavioral treatment, medical device or other) that, in the judgment of the investigator, could affect the outcome of this study.
✕. Potential participant is pregnant or breastfeeding.
✕. Potential participant has claustrophobia or implantation with any medical devices above the waist that may concentrate radio frequency fields or have other medical issues that may frustrate participation in MRI/PET imaging procedures.
✕. Potential participant has a history of large vessel stroke with significant residual motor or cognitive impairment.

What they're measuring

Change in Global cholinergic signaling using [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET)

Timeframe: at 3 months (post-intervention)

Trial details

NCT IDNCT07243600

SponsorPosit Science Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-05-31

Contact for this trial

Sarah-Jane Grant, MA

415-539-3130 sarah-jane.grant@positscience.com

View on ClinicalTrials.gov More Mild Cognitive Impairment trials